CareDx Shares Rise After Surveillance Testing Coverage Affirmed

MT Newswires Live
07/17

CareDx (CDNA) shares were up over 30% in Thursday trading after the company said a final policy affirmed coverage across its transplant surveillance offerings in kidney, heart, and lung.

The firm reported earlier the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection.

The final Local Coverage Determination is expected to take effect on Aug. 30, CareDx added.

Price: 39.01, Change: +9.26, Percent Change: +31.11

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10